Drug Profile
Research programme: polyclonal antibody therapies - Excelimmune
Alternative Names: StaphguardLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Excelimmune
- Class Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (Intraperitoneal)
- 21 Dec 2011 Preclinical development is ongoing in USA